Alembic Pharmaceuticals has received a formal warning letter from the U.S. Food and Drug Administration targeting its bioequivalence research facility in Vadodara, India. The warning letter, dated July 10, 2026, follows an FDA inspection of the Alembic Research Centre Bioequivalence facility conducted between March
Skadden Arps faces mounting political pressure over its conflict of interest concerns
Andy Burnham is planning to return Jonathan Reynolds to the role of
Britain’s buy now, pay later sector is entering a new era after
